Want to see IN:NATCAPSUQ full AI Analyst Report?
NATCAPSUQ Stock Chart & Stats
₹145.15
-₹1.02(-0.69%)
At close: 4:00 PM EDT
₹145.15
-₹1.02(-0.69%)
Day’s Range― - ―
52-Week Range₹135.60 - ₹296.40
Previous CloseN/A
Volume10.41K
Average Volume (3M)8.08K
Market Cap
₹1.53B
Enterprise Value₹2.74K
Total Cash (Recent Filing)₹53.75M
Total Debt (Recent Filing)₹1.12B
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Oct 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.25
Shares Outstanding10,411,154
10 Day Avg. Volume870
30 Day Avg. Volume8,081
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)0.55
P/FCF Ratio-9.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthFY2026 revenue growth indicates the company expanded sales despite later profitability pressure. Sustained top-line progress can support operating leverage and strengthen market reach, but future benefit depends on restoring margins.
Moderate LeverageDebt at roughly half of equity leaves more balance-sheet flexibility than a highly leveraged structure. This may help the company fund operations while addressing losses, although declining equity means the cushion could narrow if losses persist.
Established Drug Manufacturing FocusOperating in specialty and generic drug manufacturing places the company in an established healthcare supply segment. This provides a defined commercial focus and potential recurring demand, though the pack gives no evidence of competitive advantage.
Bears Say
Sharp Profitability DeteriorationGross-margin compression and a shift from near break-even to a sizable net loss show that recent growth is not translating into earnings. Negative operating and EBITDA margins indicate cost, pricing, or mix pressure that could persist without a turnaround.
Weak Cash GenerationOperating cash flow fell to a very low level and free cash flow was negative in both years. Weak internal cash generation can constrain investment and increase reliance on external funding to sustain operations or growth.
Declining Equity And Negative ROEEquity declined year over year and ROE turned negative in FY2026 because of the loss. Persistent erosion would reduce financial resilience and make future capital needs more dilutive or costly over time.
Natural Capsules Limited News
NATCAPSUQ FAQ
What was Natural Capsules Limited’s price range in the past 12 months?
Natural Capsules Limited lowest stock price was ₹135.60 and its highest was ₹296.40 in the past 12 months.
What is Natural Capsules Limited’s market cap?
Natural Capsules Limited’s market cap is ₹1.53B.
When is Natural Capsules Limited’s upcoming earnings report date?
Natural Capsules Limited’s upcoming earnings report date is Oct 26, 2026 which is in 65 days.
How were Natural Capsules Limited’s earnings last quarter?
Natural Capsules Limited released its earnings results on Aug 12, 2026. The company reported -₹3.819 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Natural Capsules Limited overvalued?
According to Wall Street analysts Natural Capsules Limited’s price is currently Overvalued.
Does Natural Capsules Limited pay dividends?
Natural Capsules Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Natural Capsules Limited dividends here
What is Natural Capsules Limited’s EPS estimate?
Natural Capsules Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Natural Capsules Limited have?
Natural Capsules Limited has 10,411,154 shares outstanding.
What happened to Natural Capsules Limited’s price movement after its last earnings report?
Natural Capsules Limited reported an EPS of -₹3.819 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.671%.
Which hedge fund is a major shareholder of Natural Capsules Limited?
Currently, no hedge funds are holding shares in IN:NATCAPSUQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Natural Capsules Limited
Natural Capsules Ltd. specializes in the production and global distribution of hard gelatin and cellulose capsule shells, catering to markets in India and abroad. The company offers a comprehensive array of capsule types, including those guaranteed free from bovine spongiform encephalopathy (BSE) and transmissible spongiform encephalopathy (TSE), shiny, sodium lauryl sulfate (SLS)-free, and halal-certified gelatin variants. Their product line further extends to fast-release, printed gelatin/cellulose, vegetarian, and enteric capsule shells. Beyond manufacturing shells, Natural Capsules Ltd. is also involved in formulating various pharmaceutical products in capsule dosage forms. Established in 1993, the company is headquartered in Bengaluru, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Vaishali Pharma Ltd.
―